Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice

PLoS Medicine

Volumn 5, Issue 1, 2008, Pages 0079-0089

  Denton, Paul W ^a   Estes, Jacob D ^b   Sun, Zhifeng ^a   Othieno, Florence A ^a   Wei, Bangdong L ^a   Wege, Anja K ^a   Powell, Daniel A ^a   Payne, Deborah ^a   Haase, Ashley T ^b   Garcia, J Victor ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENITAL SYSTEM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTESTINE LYMPHATIC TISSUE; LIVER CELL; MOUSE; NONHUMAN; PROPHYLAXIS; VAGINITIS; VIRUS TRANSMISSION; ANIMAL; DISEASE MODEL; DISEASE TRANSMISSION; DRUG SCREENING; FEMALE GENITAL SYSTEM; FETAL TISSUE TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; INTRAVAGINAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; LIVER TRANSPLANTATION; MOUSE MUTANT; MOUSE STRAIN; MUCOSAL IMMUNITY; PATHOGENICITY; RADIATION CHIMERA; SPECIES DIFFERENCE; THYMUS; TRANSPLANTATION; VIROLOGY; XENOGRAFT;

ADENINE; ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-HIV AGENTS; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; FETAL TISSUE TRANSPLANTATION; GENITALIA, FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; LIVER TRANSPLANTATION; MICE; MICE, INBRED STRAINS; MICE, SCID; ORGANOPHOSPHONATES; RADIATION CHIMERA; SPECIES SPECIFICITY; THYMUS GLAND; TRANSPLANTATION, HETEROLOGOUS;

EID: 38849136442     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050016     Document Type: Article

References (51)

1. WHO-UNAIDS (2007) 2007 AIDS Epidemic Update. Geneva, Switzerland: UNAIDS.
2. Veazey RS, Springer MS, Marx PA, Dufour J, Klasse PJ, et al. (2005) Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 11: 1293-1294.
3. Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, et al. (2006) Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 194: 904-911.
4. Derdelinckx I, Wainberg MA, Lange JM, Hill A, Halima Y, et al. (2006) Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med 3: e454. doi:10.1371/journal.pmed.0030454
5. Gupta K, Klasse PJ (2006) How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked? PLoS Med 3: e79. doi:10.1371/journal.pmed.0030079
6. Miller CJ, Alexander NJ, Sutjipto S, Lackner AA, Gettie A, et al. (1989) Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J Virol 63: 4277-4284.
7. Pauza CD, Horejsh D, Wallace M (1998) Mucosal transmission of virulent and avirulent lentiviruses in macaques. AIDS Res Hum Retroviruses 14: S83-S87.
8. Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7: 118-130.
9. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, et al. (2005) Development of functional human blood and immune systems in NOD/ SCID/IL2 receptor {gammag} chain(null) mice. Blood 106: 1565-1573.
10. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, et al. (2004) Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304: 104-107.
11. Aldrovandi GM, Feuer G, Gao L, Jamieson B, Kristeva M, et al. (1993) The SCID-hu mouse as a model for HIV-1 infection. Nature 363: 732-736.
12. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, et al. (1988) The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241: 1632-1639.
13. Stoddart CA, Bales CA, Bare JC, Chkhenkeli G, Galkina SA, et al. (2007) Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PLoS ONE 2: e655. doi:10.1371/journal.pone.0000655
14. Vandekerckhove BA, Krowka JF, McCune JM, de Vries JE, Spits H, et al. (1991) Clonal analysis of the peripheral T cell compartment of the SCID-hu mouse. J Immunol 146: 4173-4179.
15. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, et al. (2006) Humanized mice mount specific adaptive and innate immune response to EBV and TSST-1. Nat Med 12: 1316-1322.
16. Sun Z, Denton PW, Estes JD, Othieno FA, Wege AK, et al. (2007) Intrarectal transmission, systemic infection and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 204: 705-714.
17. Lan P, Tonomura N, Shimizu A, Wang S, Yang YG (2006) Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 108: 487-492.
18. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, et al. (1987) Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236: 819-822.
19. Fredericksen BL, Wei BL, Yao J, Luo T, Garcia JV (2002) Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol 76: 11440-11446.
20. Wei BL, Denton PW, O'Neill E, Luo T, Foster JL, et al. (2005) Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J Virol 79: 5705-5712.
21. Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, et al. (2001) Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis 28: 417-423.
22. Frick LW, Lambe CU, St John L, Taylor LC, Nelson DJ (1994) Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2′R,5′S-)-cis-5-fluoro-1- [2-(hydroxymethyl)-1,3- oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. Antimicrob Agents Chemother 38: 2722-2729.
23. Naesens L, Bischofberger N, Augustijns P, Annaert P, Van den Mooter G, et al. (1998) Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother 42: 1568-1573.
24. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, et al. (2005) Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 434: 1148-1152.
25. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, et al. (2005) Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 79: 9217-9227.
26. Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, et al. (2007) Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26: 257-270.
27. Hu J, Gardner MB, Miller CJ (2000) Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 74: 6087-6095.
28. Poonia B, Wang X, Veazey RS (2006) Distribution of simian immunodeficiency virus target cells in vaginal tissues of normal rhesus macaques: implications for virus transmission. J Reprod Immunol 72: 74-84.
29. Givan AL, White HD, Stern JE, Colby E, Gosselin EJ, et al. (1997) Flow cytometric analysis of leukocytes in the human female reproductive tract: comparison of fallopian tube, uterus, cervix, and vagina. Am J Reprod Immunol 38: 350-359.
30. Johansson EL, Rudin A, Wassen L, Holmgren J (1999) Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology 96: 272-277.
31. De Clercq E (2007) The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res 75: 1-13.
32. Lu Y, Brosio P, Lafaile M, Li J, Collman RG, et al. (1996) Vaginal transmission of chimeric simian/human immunodeficiency viruses in rhesus macaques. J Virol 70: 3045-3050.
33. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C (1999) Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284: 816-819.
34. Hsu M, Ho SH, Balfe P, Gettie A, Harouse J, et al. (2005) A CCR5-tropic simian-HIV molecular clone capable of inducing AIDS in rhesus macaques. J Acquir Immune Defic Syndr 40: 383-387.
35. Anton PA, Elliott J, Poles MA, McGowan IM, Matud J, et al. (2000) Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 14: 1761-1765.
36. Cranston RD, Anton PA, McGowan IM, Elliott J, Poles MA, et al. (2000) Gastrointestinal mucosal biopsy in HIV disease and AIDS. Gastrointest Endosc Clin N Am 10: 637-667.
37. Veazey RS, Mansfield KG, Tham IC, Carville AC, Shvetz DE, et al. (2000) Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection. J Virol 74: 11001-11007.
38. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. (2004) CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200: 749-759.
39. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, et al. (2004) Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200: 761-770.
40. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, et al. (2003) Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 77: 11708-11717.
41. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, et al. (2005) Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434: 1093-1097.
42. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, et al. (2005) Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438: 99-102.
43. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L (2007) Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 146: 591-601.
44. Liu AY, Grant RM, Buchbinder SP (2006) Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA 296: 863-865.
45. Grant RM, Buchbinder S, Cates W Jr, Clarke E, Coates T, et al. (2005) AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science 309: 2170-2171.
46. Youle M, Wainberg MA (2003) Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS 17: 937-938.
47. Dao H, Mofenson LM, Ekpini R, Gilks CF, Barnhart M, et al. (2007) International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol 197: S42-55.
48. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, et al. (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354: 795-802.
49. Stone A, Jiang S (2006) Microbicides: stopping HIV at the gate. Lancet 368: 431-433.
50. Di Fabio S, Giannini G, Lapenta C, Spada M, Binelli A, et al. (2001) Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. AIDS 15: 2231-2238.
51. Mosier DE, Gulizia RJ, Baird SM, Wilson DB, Spector DH, et al. (1991) Human immunodeficiency virus infection of human-PBL-SCID mice. Science 251: 791-794.